0.97
-0.13(-11.82%)
Currency In USD
| Previous Close | 1.1 |
| Open | 1.09 |
| Day High | 1.12 |
| Day Low | 0.96 |
| 52-Week High | 4.94 |
| 52-Week Low | 0.96 |
| Volume | 1.81M |
| Average Volume | 630,912 |
| Market Cap | 55.05M |
| PE | -0.87 |
| EPS | -1.12 |
| Moving Average 50 Days | 1.82 |
| Moving Average 200 Days | 1.71 |
| Change | -0.13 |
If you invested $1000 in TScan Therapeutics, Inc. (TCRX) since IPO date, it would be worth $92.38 as of November 18, 2025 at a share price of $0.97. Whereas If you bought $1000 worth of TScan Therapeutics, Inc. (TCRX) shares 3 years ago, it would be worth $449.07 as of November 18, 2025 at a share price of $0.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
GlobeNewswire Inc.
Nov 05, 2025 12:00 PM GMT
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
GlobeNewswire Inc.
Nov 03, 2025 11:30 AM GMT
Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readou
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage bi